Short Interest in BioRestorative Therapies, Inc. (NASDAQ:BRTX) Drops By 43.4%

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a significant decline in short interest during the month of March. As of March 15th, there was short interest totalling 405,200 shares, a decline of 43.4% from the February 28th total of 715,900 shares. Based on an average daily volume of 371,800 shares, the short-interest ratio is currently 1.1 days. Approximately 8.1% of the shares of the company are sold short.

Institutional Investors Weigh In On BioRestorative Therapies

An institutional investor recently bought a new position in BioRestorative Therapies stock. Citadel Advisors LLC acquired a new stake in BioRestorative Therapies, Inc. (NASDAQ:BRTX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 21,481 shares of the company’s stock, valued at approximately $31,000. Citadel Advisors LLC owned about 0.31% of BioRestorative Therapies at the end of the most recent quarter. Institutional investors own 69.38% of the company’s stock.

BioRestorative Therapies Stock Performance

NASDAQ:BRTX traded down $0.02 during trading on Friday, reaching $1.81. The company’s stock had a trading volume of 21,475 shares, compared to its average volume of 666,632. BioRestorative Therapies has a 12 month low of $1.03 and a 12 month high of $2.55. The firm has a market cap of $12.53 million, a price-to-earnings ratio of -1.18 and a beta of 64.37. The firm has a 50 day moving average of $1.97 and a 200-day moving average of $1.72.

BioRestorative Therapies (NASDAQ:BRTX) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.07. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 98.49%. The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.48 million. Equities research analysts forecast that BioRestorative Therapies will post -1.43 earnings per share for the current fiscal year.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.